Less bleeding seen with rivaroxaban in large lung clot study

03/27/2012 | Reuters

The anticoagulant rivaroxaban is safer than and works as well as standard dual therapy for blood clots of the lung, according to a 4,833-patient study presented at a cardiology meeting. A lower percentage of patients taking rivaroxaban experienced major and minor bleeding compared with those who took the combination therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY